secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001013762-25-002413
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Rafael Holdings completes merger with Cyclo Therapeutics after shareholder approvals
--------------------------------------------------------------------------------

- Cyclo shareholders received 0.3525 shares of Rafael Class B common stock per share; Rafael issued approximately 7,132,228 shares.
- Cyclo's Phase 3 TransportNPC trial for Niemann-Pick Type C1 is fully enrolled; 48-week interim analysis expected mid-2025.
- Markus W. Sieger, former Cyclo Chairman, appointed to Rafael board as independent director.
- Certain Cyclo warrants converted into Rafael warrants; new warrants to be publicly traded on NYSE American around March 31, 2025.
- Cyclo common stock (CYTH) suspended from Nasdaq as of March 25, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000101376225002413/0001013762-25-002413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000101376225002413/ea0235617-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-002413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer